FUTURE OF HEALTHCARE
Skylight Health Group | December 14, 2022
Skylight Health Group Inc. a healthcare platform combining technology and analytics focused on transitioning patients into value based care to drive better health outcomes and experiences in the United States, announced that its Board of Directors has authorized, and the Company has declared, a dividend on its 9.25% Series A Cumulative Redeemable Perpetual Preferred Shares for the month of January 2023. The Series A Preferred Shares trade under the “SLHGP” stock ticker symbol.
In accordance with the terms of the Series A Preferred Shares, the Series A dividend will be payable in cash in the amount of $0.1927 per share on January 20, 2023 to the shareholders of record of the Series A Preferred Stock as of the dividend record date of December 30, 2022.
The Company also wishes to update details of the Company’s previously announced shares for debt on September 15 and 16, 2022. The Company will settle a total of $438,400 in debt by issuing an aggregate of 626,286 common shares to the creditors at a deemed price of $0.70 per common share, in satisfaction of the debt.
About Skylight Health Group
Skylight Health Group is a healthcare services and technology company, working to positively impact patient health outcomes. The Company operates a US multi-state primary care health network comprised of physical practices providing a range of services from primary care, sub-specialty, allied health, and laboratory/diagnostic testing. The Company is focused on helping small and independent practices shift from a traditional fee-for-service model to value-based care (“VBC”) through tools including proprietary technology, data analytics and infrastructure. In an FFS model, payors (commercial and government insurers) reimburse on an encounter-based approach. This puts a focus on the volume of patients per day. In a VBC model, the providers offer care that is aimed at keeping patients healthy and minimizing unnecessary health expenditures that are not proven to maintain the patient’s well-being. This places emphasis on quality over volume. VBC will lead to improved patient outcomes, reduced cost of delivery and drive stronger financial performance from existing practices.
DIGITAL HEALTHCARE, MEDICAL DEVICES
mPulse Mobile, | December 16, 2022
mPulse Mobile, a leader in conversational AI and digital engagement solutions for the healthcare industry, announced the launch of new content capabilities and streaming courses that address health literacy barriers in a consumer-friendly format.
Several solution advances continue mPulse’s focus on integrating streaming content into digital health engagement strategies, creating an industry-leading combination of conversational AI that drives two-way SMS messaging campaigns and powerful health streaming content to engage, delight, and move consumers to adopt healthy behaviors.
“Stories” Video Format
mPulse launched the stories video format to deliver more impactful content experiences in consumer-focused outreach programs. The format adapts video “stories” commonly seen in social media platforms like TikTok and Instagram Reels to deliver captivating content on important healthcare topics. mPulse’s Health Activation Platform tailors the stories content to the individual to address important engagement challenges such as medication adherence, gaps in care, and health plan navigation.
“These new video capabilities are proof that mPulse Mobile continues to pioneer category-defining member engagement technology. Our highly tailored, consumer focused content is a powerful tool that creates culturally sensitive digital experiences to address health disparities, encourage healthy behaviors, and drive member outcomes. The stories format allows us to be more impactful when consumers engage, and our initial results show they have a significant impact on program goals.”
Bob Farrell, CEO of mPulse Mobile
The format drives increased engagement and improved health outcomes among targeted populations.
mPulse deployed the stories format in a diabetes eye-screening outreach program. The program included 200,000 Medicare Advantage members, with a subset of 100,000 members receiving the streaming content, delivered in a stories format. This cohort showed a 274% higher Call to Action completion rate than members who did not receive the stories-formatted content.
Leveraging conversational outreach, consumers are prompted on the issues that might be preventing them from completing a given action. When they respond via text to identify a barrier, tailored streaming content is delivered instantly and in real-time via an embedded link to address the barrier.
New Health Educational Courses
mPulse has also launched new streaming health courses that address key health issues and improve health literacy in a consumer-friendly digital format. Produced with proven learning techniques and behavioral science, these courses allow healthcare organizations to extend the digital experience from initial outreach to deep, relationship-building experiences.
“Our product strategy aims to offer the most effective technology at delivering health engagement, and core to mPulse’s value is meaningful digital content, which elevates engagement experiences to a new level,” said Sanjeev Sawai, Chief Product and Technology Officer at mPulse Mobile. “Members are in need of better educational content that they find engaging and worth their time. We use short, captivating content to get members' attention and motivate them to act in healthy ways - ways that help them build their health literacy, prevent diseases, manage conditions, and foster wellbeing. Our approach offers innovative frictionless ways to encourage members to engage deeply in their own health and healthcare.”
About mPulse Mobile
mPulse Mobile is reimagining health engagement to inspire healthier lives and deeper relationships between healthcare organizations and their consumers. A leading healthcare Conversational AI platform combines with award-winning health education for the streaming age to deliver tailored digital health engagement that nurtures, educates, and activates healthcare consumers. With more than a decade of experience, 150+ healthcare customers and 1 billion conversations annually, mPulse Mobile has the data, the expertise, and the solutions to drive healthy behavior change.
ASEP Medical Holdings Inc | November 25, 2022
Asep Medical Holdings Inc. is pleased to announce that, for recruitment, incentivization, and retention purposes, it has granted to certain officers and advisors an aggregate of 1,080,000 stock options to purchase up to 1,080,000 common shares of the Company of which 200,000 are exercisable at a price of $0.30 per Share until September 29, 2032, 200,000 are exercisable at a price of $0.30 per share until October 1, 2032, and 680,000 are exercisable at a price of $0.30 per share until November 24, 2032.
ABOUT ASEP MEDICAL HOLDINGS INC
Asep Inc. is dedicated to addressing antibiotic failure by developing novel solutions for significant unmet medical needs. The Company is a consolidation of two existing private companies that are both in the advanced development of both proprietary diagnostic tools, enabling the early and timely identification of severe sepsis as well as broad-spectrum therapeutic agents to address multidrug-resistant biofilm infections.
Sepset Biosciences Inc. is developing a diagnostic technology that involves a patient gene expression signature that predicts severe sepsis, one of the significant diseases leading to antibiotic failure since antibiotics are the primary treatment for sepsis. Despite this, sepsis is responsible for nearly 20% of all deaths on the planet. The semester test is a blood-based gene expression assay that is straightforward to implement, and results are obtained in about an hour in the emergency room or intensive care unit. This proprietary diagnostic technology differs from current diagnostic tests in enabling diagnosis of severe sepsis within 1-2 hours of first clinical presentation while other diagnostics only provide diagnosis after 24-36 hours. Asep Inc. believes this will enable critical early decisions to be made by physicians regarding appropriate therapies and reduce overall morbidity and mortality due to sepsis.
ABT Innovations Inc.'s peptide technology covers a broad range of therapeutic applications, including bacterial biofilm infections anti-inflammatories, anti-infective immune modulators, and vaccine adjuvants.
FUTURE OF HEALTHCARE, DIGITAL HEALTHCARE
MVIS® Global Bionic Healthcare ESG Index | December 08, 2022
MarketVector IndexesTM announced the licensing of the MVIS® Global Bionic Healthcare ESG Index to underlie the VanEck Bionic Engineering UCITS ETF.
The MVIS® Global Bionic Healthcare ESG Index includes companies that generate at least 50% of their revenue from medical, dental, or vision-related implants, bioprinting, prosthesis, or preservation of organs and tissue.
“We have observed sound growth in the global bionics market which includes a range of niche healthcare solutions from medical implants to prostheses and bioprinting. These innovations in medical technology open new horizons to meet the rising needs of an aging population, significantly improve the quality of life for people with disabilities, and pave the way for the discovery of potentially life-saving treatments. The MVIS® Global Bionic Healthcare ESG Index offers an investable benchmark to track the leading companies in this industry.”
Mirela Stefanova, Manager of Equity Operations at MarketVector
The MVIS® Global Bionic Healthcare ESG Index is weighted by free float market capitalization and reviewed on a quarterly basis. The index is calculated in USD as a price index and a total return net index. Capping factors are applied to avoid overweighting of single index components.
“The proportion of the elderly population is rising and with it the demand for technical solutions such as hearing and visual aids, pacemakers, artificial joints and the like that improve the quality of life in the old age,” says Martijn Rozemuller, CEO at VanEck Europe. “At the same time, increasingly available bionic tools are helping people with chronic diseases such as diabetes or functional disorders.”
About MarketVector Indexes
MarketVector IndexesTM is a regulated Benchmark Administrator in Europe, incorporated in Germany and registered with the Federal Financial Supervisory Authority (BaFin). MarketVector maintains indexes under the MarketVectorTM, MVIS® and BlueStar® names. With a mission to accelerate index innovation globally, MarketVector is best known for its broad suite of Thematic indexes, a long-running expertise in Hard Asset-linked Equity indexes, and its pioneering Digital Asset index family. MarketVector is proud to be in partnership with more than 25 Exchange Traded Product issuers and index fund managers in markets throughout the world, with approximately USD 26.99 billion in assets under management.